The Effects of the L / N-Type Calcium Channel Blocker (Cilnidipine) on Sympathetic Hyperactive Morning Hypertension: Results From ACHIEVE-ONE

Authors

  • Kazuomi Kario MD,

    1. From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, School of Medicine, Tochigi ; 1Division of Cardiology, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka ; 2Meimai Central Hospital, Akashi ; 3Osaka General Hospital of West Japan Railway Company, Osaka ; 4Higashi Takarazuka Satoh Hospital, Takarazuka ; 5Sendai City Hospital, Sendai ; 6Hino Memorial Hospital, Shiga ; 7Toranomon Hospital, Tokyo ; 8Japanese Red Cross Society Azumino Hospital, Azumino, Nagano ; 9 and Osaka General Medical Center, Osaka, Japan10
    Search for more papers by this author
  • 1 Shin-ichi Ando MD,

    1. From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, School of Medicine, Tochigi ; 1Division of Cardiology, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka ; 2Meimai Central Hospital, Akashi ; 3Osaka General Hospital of West Japan Railway Company, Osaka ; 4Higashi Takarazuka Satoh Hospital, Takarazuka ; 5Sendai City Hospital, Sendai ; 6Hino Memorial Hospital, Shiga ; 7Toranomon Hospital, Tokyo ; 8Japanese Red Cross Society Azumino Hospital, Azumino, Nagano ; 9 and Osaka General Medical Center, Osaka, Japan10
    Search for more papers by this author
  • 2 Hidenori Kido MD,

    1. From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, School of Medicine, Tochigi ; 1Division of Cardiology, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka ; 2Meimai Central Hospital, Akashi ; 3Osaka General Hospital of West Japan Railway Company, Osaka ; 4Higashi Takarazuka Satoh Hospital, Takarazuka ; 5Sendai City Hospital, Sendai ; 6Hino Memorial Hospital, Shiga ; 7Toranomon Hospital, Tokyo ; 8Japanese Red Cross Society Azumino Hospital, Azumino, Nagano ; 9 and Osaka General Medical Center, Osaka, Japan10
    Search for more papers by this author
  • 3 Jin Nariyama MD,

    1. From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, School of Medicine, Tochigi ; 1Division of Cardiology, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka ; 2Meimai Central Hospital, Akashi ; 3Osaka General Hospital of West Japan Railway Company, Osaka ; 4Higashi Takarazuka Satoh Hospital, Takarazuka ; 5Sendai City Hospital, Sendai ; 6Hino Memorial Hospital, Shiga ; 7Toranomon Hospital, Tokyo ; 8Japanese Red Cross Society Azumino Hospital, Azumino, Nagano ; 9 and Osaka General Medical Center, Osaka, Japan10
    Search for more papers by this author
  • 4 Shin Takiuchi MD,

    1. From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, School of Medicine, Tochigi ; 1Division of Cardiology, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka ; 2Meimai Central Hospital, Akashi ; 3Osaka General Hospital of West Japan Railway Company, Osaka ; 4Higashi Takarazuka Satoh Hospital, Takarazuka ; 5Sendai City Hospital, Sendai ; 6Hino Memorial Hospital, Shiga ; 7Toranomon Hospital, Tokyo ; 8Japanese Red Cross Society Azumino Hospital, Azumino, Nagano ; 9 and Osaka General Medical Center, Osaka, Japan10
    Search for more papers by this author
  • 5 Tetsuo Yagi MD,

    1. From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, School of Medicine, Tochigi ; 1Division of Cardiology, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka ; 2Meimai Central Hospital, Akashi ; 3Osaka General Hospital of West Japan Railway Company, Osaka ; 4Higashi Takarazuka Satoh Hospital, Takarazuka ; 5Sendai City Hospital, Sendai ; 6Hino Memorial Hospital, Shiga ; 7Toranomon Hospital, Tokyo ; 8Japanese Red Cross Society Azumino Hospital, Azumino, Nagano ; 9 and Osaka General Medical Center, Osaka, Japan10
    Search for more papers by this author
  • 6 Toshiki Shimizu MD,

    1. From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, School of Medicine, Tochigi ; 1Division of Cardiology, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka ; 2Meimai Central Hospital, Akashi ; 3Osaka General Hospital of West Japan Railway Company, Osaka ; 4Higashi Takarazuka Satoh Hospital, Takarazuka ; 5Sendai City Hospital, Sendai ; 6Hino Memorial Hospital, Shiga ; 7Toranomon Hospital, Tokyo ; 8Japanese Red Cross Society Azumino Hospital, Azumino, Nagano ; 9 and Osaka General Medical Center, Osaka, Japan10
    Search for more papers by this author
  • 7 Kazuo Eguchi MD,

    1. From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, School of Medicine, Tochigi ; 1Division of Cardiology, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka ; 2Meimai Central Hospital, Akashi ; 3Osaka General Hospital of West Japan Railway Company, Osaka ; 4Higashi Takarazuka Satoh Hospital, Takarazuka ; 5Sendai City Hospital, Sendai ; 6Hino Memorial Hospital, Shiga ; 7Toranomon Hospital, Tokyo ; 8Japanese Red Cross Society Azumino Hospital, Azumino, Nagano ; 9 and Osaka General Medical Center, Osaka, Japan10
    Search for more papers by this author
  • 1 Minoru Ohno MD,

    1. From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, School of Medicine, Tochigi ; 1Division of Cardiology, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka ; 2Meimai Central Hospital, Akashi ; 3Osaka General Hospital of West Japan Railway Company, Osaka ; 4Higashi Takarazuka Satoh Hospital, Takarazuka ; 5Sendai City Hospital, Sendai ; 6Hino Memorial Hospital, Shiga ; 7Toranomon Hospital, Tokyo ; 8Japanese Red Cross Society Azumino Hospital, Azumino, Nagano ; 9 and Osaka General Medical Center, Osaka, Japan10
    Search for more papers by this author
  • 8 Osamu Kinoshita MD,

    1. From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, School of Medicine, Tochigi ; 1Division of Cardiology, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka ; 2Meimai Central Hospital, Akashi ; 3Osaka General Hospital of West Japan Railway Company, Osaka ; 4Higashi Takarazuka Satoh Hospital, Takarazuka ; 5Sendai City Hospital, Sendai ; 6Hino Memorial Hospital, Shiga ; 7Toranomon Hospital, Tokyo ; 8Japanese Red Cross Society Azumino Hospital, Azumino, Nagano ; 9 and Osaka General Medical Center, Osaka, Japan10
    Search for more papers by this author
  • and 9 Takahisa Yamada MD 10

    1. From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, School of Medicine, Tochigi ; 1Division of Cardiology, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka ; 2Meimai Central Hospital, Akashi ; 3Osaka General Hospital of West Japan Railway Company, Osaka ; 4Higashi Takarazuka Satoh Hospital, Takarazuka ; 5Sendai City Hospital, Sendai ; 6Hino Memorial Hospital, Shiga ; 7Toranomon Hospital, Tokyo ; 8Japanese Red Cross Society Azumino Hospital, Azumino, Nagano ; 9 and Osaka General Medical Center, Osaka, Japan10
    Search for more papers by this author

Errata

This article is corrected by:

  1. Errata: Erratum Volume 15, Issue 8, 610, Article first published online: 31 May 2013

  • A part of this study was presented at the 34th Annual Scientific Meeting of the Japanese Society of Hypertension, Utsunomiya, Japan, October 20–22, 2011.

Kazuomi Kario, MD, Jichi Medical University, School of Medicine, 3311-1 Yakushiji, Shimotsuke, 329-0498 Tochigi, Japan
E-mail:kkario@jichi.ac.jp

Abstract

The Ambulatory Blood Pressure Control and Home Blood Pressure (Morning and Evening) Lowering By N-Channel Blocker Cilnidipine (ACHIEVE-ONE) trial is a large-scale clinical study on blood pressure (BP) and pulse rate (PR) in the real world with use of cilnidipine, a unique L/N-type Ca channel blocker, possessing a suppressive action on increased sympathetic activity in patients with essential hypertension. The effects of cilnidipine on morning hypertension were examined. The authors examined 2319 patients treated with cilnidipine for 12 weeks. Clinic systolic BP (SBP) decreased by 19.6 mm Hg from 155.0 mm Hg, whereas morning SBP decreased by 17.0 mm Hg from 152.9 mm Hg after 12-week cilnidipine treatment. Cilnidipine reduced both morning SBP and PR more markedly in patients with higher baseline morning SBP (−3.2 mm Hg and −1.3 beats per minute in the first quartile of morning SBP, −30.9 mm Hg and −3.2 beats per minute in the fourth quartile), and also reduced both morning PR and SBP more markedly in patients with higher baseline morning PR (0.6 beats per minute and −15.6 mm Hg in <70 beats per minute, and −9.7 beats per minute and −20.2 mm Hg in ≥85 beats per minute). Cilnidipine significantly reduced BP and PR in hypertensive patients at the clinic and at home, especially with higher BP and PR in the morning. J Clin Hypertens (Greenwich). 2012; 00:00–00. ©2012 Wiley Periodicals, Inc.

Ancillary